ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage

 
Print Page
Email Article

Alzheimer's Vaccine to Advance to Exploratory Phase Two Studies

  [ 5 votes ]   [ Discuss This Article ]
www.ProHealth.com • August 10, 2001



The promising Alzheimer’s immunotherapy drug AN-1792 has completed the first phase of safety experiments and will soon enter into a second round of studies. This was according to a July 2001 announcement by the Elan Corporation and Wyeth-Ayerst Laboratories.

In the Phase 1 safety studies, the AN-1792 vaccine had been administered to more than 100 patients with mild to moderate Alzheimer's disease in a variety of dosage regimens. The results obtained indicate that the vaccine is well tolerated and that a portion of patients developed a sufficient immunological response to AN-1792 to warrant the initiation of the additional study.

Elan and American Home Products Corporation plan to initiate a multicentre exploratory Phase 2A clinical study with approximately 375 patients with mild to moderate Alzheimer's disease at sites in the US and Europe.

This study is designed to measure the immune response to the beta amyloid peptide and assess the impact on a range of cognitive, physiological, and biological markers of Alzheimer's disease. Patients with mild to moderate Alzheimer's disease will be enrolled and evaluated using conventional cognitive tests and by other surrogate measures.

These results produced verbal support from organizations such as the Alzheimer’s Association.

“The Alzheimer's Association welcomes today's news that the experimental drug AN-1792 appears to be well tolerated for human use, elicits an immune response in some patients, and is ready for Phase Two clinical trials,” said Bill Thies, Ph.D., Vice President of Medical and Scientific Affairs.

“For years, scientists have hypothesized that the presence of amyloid plaques causes cell death and leads to the decline in a person's cognitive functions,” said Thies. “With this potential plaque-clearing drug, scientists now have an opportunity to test this theory and take a major step toward unlocking the mystery behind this devastating disease.”

It is expected this study will commence in the third quarter of 2001 and take approximately two years to complete. The interim and final results of this study are expected to provide additional information regarding AN-1792, as well as valuable information useful for the development of other therapeutic agents being studied as part of the collaborative development program.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® FibroSleep™ Optimized Curcumin Longvida®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
Quercetin: Natural Support for Allergy & Inflammation Relief and More Quercetin: Natural Support for Allergy & Inflammation Relief and More
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map